Arc en Diabetes 2016

 PRE-PROGRAMA 

VIERNES 19 DE FEBRERO

 

15:30-15:40    Bienvenida

                      

15:40-16:00    Presentación de abstracts sobre sitagliptina 2015

                       Dr. Esteban Jódar Gimeno

 

16:00-16:15    Conferencia introductoria

xxxxxxxxx

Dra. Rebeca Reyes

 

16:15-17:45    Módulo 1. Sesiones plenarias

                       Moderador: Dr. Manuel Muñoz Torres

 

Dr. Alberto Moreno Carazo

[ADA Diabetes Care Symposium] Novel Clinical Interventions in Therapy That Impact the Management of Diabetes

 

Dr. Elías Delgado Álvarez

[EASD/ESC] Symposium Lesson leaarned from glucose lowering trials

 

Dr. Javier Escalada San Martín

[EASD] The liver in focus

 

Dra. Noemí González Pérez de Villar

[ADA] Cardiovascular disease risk factor management in type 2 diabetes mellitus. Where are we in 2015?

 

Dra. Sharona Azriel Mira

[ADA] SGLT2 Blockers in 2015

 

17:45-18:15    Café

 

18:15-19:45    Módulo 2. Epidemiología, genética, obesidad y otros factores de riesgo
                       Moderador: Dr. José M.a Hernández i Anguera

 

Dr. Alberto Moreno Carazo

[ADA 65-OR] The Role of Glycemia in Insulin Resistance in Youth with Type 1 and Type 2 Diabetes

[ADA 75-OR] Early Metabolomic Profi ling Scores Improves the Prediction of Type 2 Diabetes in the Prospective D.E.S.I.R. Study

 

Dr. Elías Delgado Álvarez

[EASD 49] Consecuencias económicas de la inercia terapéutica en UK

[EASD 17] Riesgo de ca de páncreas y tratamientos antidiabéticos en la cohorte danesa

 

Dr. Javier Escalada San Martín

[EASD 10] Glycaemic control and incidence of dementia in 363,573 patients with type 2 diabetes: an observational study

[EASD 120] Epigenetic effects of maternal type 1 diabetes: placental dna methylations, mirnas and their effect on gene expression |

 

Dra. Noemí González Pérez de Villar

[ECE] Nocturnal blood pressure cut off points related to the development of microvascular complications and arterial hypertension in patients with type 1 diabetes

[ECE] Insulin-induced lipohypertrophy diagnostics in diabetic patients: subcutaneous fat ultrasonography

 

Dra. Sharona Azriel Mira

[ADA 124-lb] Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.

[ADA 55-OR] Surveillance of Cardiovascular Events and Total Mortality among Insured Adults With and Without Diabetes: The SUPREME Cohort Study

 

21:30   Cena

 

SÁBADO 20 DE FEBRERO

 

09:30-11:00    Módulo 3. Clínica y tratamiento (I)

                       Moderador: Dr. Pedro Mezquita Raya

 

Dr. Alberto Moreno Carazo

[ADA 77-OR] Incidence of Diabetes among Spouses of People with Diabetes

[ADA 93-OR] Basal Insulin Peglispro (BIL) Is Superior to Insulin Glargine (GL) in Reducing HbA1c at 52 Wks in Insulin-Naïve T2D Patients (Pts) Treated with Oral Antihyperglycemic Medications (OAMs): IMAGINE 2

 

Dr. Elías Delgado Álvarez

[EASD 53] Estudio de coste-eficacia entre mdi vs csii en dm 2 en Holanda

[EASD 153] Eficacia de los distintos tipos de intensificación tras el fallo de la  insulina basal

 

Dr. Javier Escalada San Martín

[EASD 16] Differential effects of glp-1 receptor agonists on 24-hour averaged heart rate in healthy volunteers and patients with type 2 diabetes

[EASD 110] Omarigliptin, a once-weekly dpp-4 inhibitor, provides similar glycaemic control to sitagliptin in patients with type 2 diabetes mellitus inadequately controlled on metformin

 

Dra. Noemí González Pérez de Villar

[ADA 72-OR] Once-weekly combination of glp-1r agonist and insulin (hm14220) offers improved glycemic control and reduced weight gain risk Jung kuk kim

[ECE] Novel glucagon receptor antagonist peptides improve glycaemic control and partially protect against streptozotocin induced diabetes in mice Finbarr o’harte

 

Dra. Sharona Azriel Mira

[ADA 76-OR] Clinical impact of itca 650 in type 2 diabetes: a randomized, double-blind, placebo-controlled, 39-week.

 

[ADA 96-OR] Unique profile of the weekly insulin hm12470: very slow onset of action, rapid off-rate similar to insulin, and absence of insulin receptor down regulation

 

11:00-11:30    Café

 

11:30-13:00    Módulo 4. Clínica y tratamiento (II)

                       Moderador: Dr. Francisco Tinahones Madueño

 

Dr. Alberto Moreno Carazo

[ADA 105-OR] A Randomized, Double-Blind, Phase 3 Trial of Dapaglifl ozin Add-on to Saxagliptin + Metformin in Type 2 Diabetes

[ADA 123-OR] Intestinal Preproglucagon Is Not Necessary for the Glucoregulatory Effects of DPP-4 Inhibitors

 

Dr. Elías Delgado Álvarez

[EASD 185] Dapa reduce albuminuria en DM2

Actualización de cetoacidosis con isglt-2

 

Dr. Javier Escalada San Martín

[EASD 122] Reactive hypoglycaemia after roux-en-y gastric bypass in type 2 diabetic subjects

[EASD 158] Efficacy and safety of alirocumab in individuals with diabetes: analyses from the odyssey long term study

 

Dra. Noemí González Pérez de Villar

[ADA 277-OR] Efficacy and Safety of Liraglutide Added to Insulin in Type 1 Diabetes: The LIRA-1 Trial

[ECE] Maintenance of risk reduction during 3-year follow up in prevention of type 2 diabetes by lifestyle intervention in primary health care setting: diabetes in europe prevention using lifestyle, physical activity and nutritional intervention (de-plan) project

 

Dra. Sharona Azriel Mira

[ADA] The evaluation of lixisenatide in acute coronary síndrome- the results of elixa.

 

[ADA 166-OR] Insulin degludec/liraglutide (ideglira) is superior to insulin glargine (ig) in a1c reduction, risk of hypoglycemia, and weight change: dual

 

 

13:00-13:15    Conferencia de cierre (¿Qué esperamos del 2016?)

Dr. Manel Puig Domingo

 

13:15   Cierre de la sesión

 

Los contenidos publicados por la Fundación redGDPS son un servicio destinado a los profesionales sanitarios de atención primaria. Los contenidos requieren de una formación especializada para su correcta interpretación. En ningún caso la información proporcionada por Fundación redGDPS reemplazará la relación de los profesionales médicos con los pacientes.
La Fundación redGDPS no promueve ninguna actividad que pueda inducir a la prescripción de marcas comerciales, uso de sistemas de determinación de glucosa o productos dietéticos.

Sociedades Afines

Blog